Xcout Intel
Umecrine Cognition competitors & alternatives
The 12 closest competitors and alternatives to Umecrine Cognition among biotechnology companies — ranked by similarity to what Umecrine Cognition actually does, not by market-cap band.
Subscribe to see Umecrine Cognition’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Umecrine Cognition
Umecrine Cognition AB is a Swedish clinical-stage pharmaceutical company based at the Karolinska Institutet Science Park in Solna, developing a novel class of drugs to treat neurological disorders of the brain.
Umecrine Cognition at a glance
Umecrine Cognition is a biotechnology company headquartered in Sweden. Its most recent funding round, Debt, raised $2.5M in July 2025. Xcout tracks 7 named people at Umecrine Cognition, including Anders Karlsson (CEO).
Umecrine Cognition leadership
- Anders KarlssonCEO
- Viktor DrvotaCEO and Chairman of the Board
- Torbjörn BäckströmFounder & Non-executive Director
- Anders BladhNon-executive Director
- Bruce F. ScharschmidtNon-executive Director
- John ÖhdNon-executive Director
1 more named person on record for Umecrine Cognition, with roles, board committees and tenure — see the full roster →
Umecrine Cognition funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Debt | $2.5M | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Umecrine Cognition competitors
Ranked by semantic similarity — how close each company is to Umecrine Cognition by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Alzinova AB is a Swedish clinical-stage biopharmaceutical company that develops disease-modifying treatments and vaccines targeting Alzheimer's disease. Utilizing its proprietary AβCC Peptide technology, the company focuses on creating therapeutics for Alzheimer's patients to address high unmet medical needs in neurodegeneration.
Biotech
BioArctic AB (publ) is an innovative Swedish research-based biopharma company headquartered in Stockholm, Sweden. Incorporated in 2000, it focuses on developing disease-modifying treatments for neurodegenerative diseases. The company is publicly traded and committed to corporate governance.
Similar biotechnology company
Ultimate Medicine AG is a Swiss preclinical biotechnology company headquartered in Zürich, focused on maximizing the healthspan of patients with Alzheimer's disease and other dementias by targeting novel toxic metabolites.
Similar biotechnology company
Recognify Life Sciences is a clinical-stage biotechnology company located in California, focusing on developing treatments for cognitive impairment associated with central nervous system disorders.
Similar biotechnology company
BioCrine AB is a drug pipeline and biotechnology research company headquartered in Solna, Sweden, operating in the endocrinology and therapeutic medical domains.
Similar biotechnology company
BioArctic AB is a Swedish biopharmaceutical company developing disease-modifying treatments for neurodegenerative disorders, particularly Alzheimer’s and Parkinson’s disease. It serves patients and healthcare systems through its own drug-development programs and partnerships with pharmaceutical companies, including Eisai.
Similar biotechnology company
Lipum AB is a clinical-stage biotechnology research company based in Umeå, Sweden, operating out of the Umeå Biotech Incubator at Uminova Science Park. The company focuses on discovering novel treatments and unique therapeutic approaches for chronic inflammatory diseases.
Similar biotechnology company
CuraSen Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies to treat neurodegenerative diseases by targeting specific receptor systems in the brain. The company's scientific approach focuses on restoring neurovascular and neuronal function to serve patients suffering from conditions such as Parkinson's disease and other neurodegenerative disorders.
Biotech
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric and neurodegenerative disorders. It uses neuroscience, data science, and biomarkers to identify and advance treatments for patients with these conditions.
Biotech
BrainZell is a Swedish biotechnology company headquartered in Stockholm that develops human brain cell models and patient-relevant brain organoids. Founded in 2020, the company leverages these advanced biological models for AI-native drug discovery to accelerate the development of life-changing therapies.
Biotech
Neumirna Therapeutics is a biotechnology company founded in 2021 and headquartered in Copenhagen, Denmark. The firm is dedicated to pioneering RNA-based therapies to treat epilepsy, Parkinson's disease, and other neurological disorders.
Similar biotechnology company
Cognition Therapeutics, Inc. is a public, clinical-stage biopharmaceutical company founded in 2007 and headquartered in Purchase, New York. The company develops therapies designed to protect neurons and advance treatments for patients living with age-related neurodegenerative diseases.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Umecrine Cognition and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Umecrine Cognitionand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →